GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.Sub-event
GSK/CureVac patent dispute adds new dimension to the existing mRNA vaccine technology focus.1 source
Keep exploring
The entities involved
-
CureVac
biopharmaceutical company in Germany
Nothing else this week.
-
GSK
British multinational pharmaceutical and biotechnology company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- Lawsuit filed alleging Pfizer engaged in deceptive marketing regarding vaccine efficacy rates.
- Pfizer and Valneva are partnering on a Lyme vaccine and are currently seeking necessary approval from the FDA.
- FDA and Pfizer are seeking regulatory approval for their products.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
Coverage
Newest first; wire copies grouped- Investing.comGSK climbs after winning FDA priority review for oral gonorrhoea antibiotic Investing.com -- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priori